Tanner Pharma Group Signs a Distribution Agreement for Partner Therapeutics’ Product, Leukine®
May 24 2018 - 8:00AM
Business Wire
Tanner Pharma Group, a global provider of integrated specialty
access solutions, has announced the signing of a distribution
agreement with Partner Therapeutics, Inc. (PTx), an integrated
biopharmaceutical company. The agreement names Tanner Pharma Group
as a distributor of Leukine® (sargramostim) in areas outside of the
United States and Canada where the product is not yet registered.
Leukine® (sargramostim) is used to help increase the number and
function of white blood cells after bone marrow
transplantation.
The ex-US-and-Canadian distribution will be managed by
TannerGAP, Inc. (“TannerGAP”), a wholly owned subsidiary of Tanner
Pharma Group. TannerGAP offers turnkey global access solutions for
the distribution of products from markets of supply to markets of
demand.
Banks Bourne, Chairman and Founder of Tanner Pharma Group,
commented, “We have customized a program for Partner Therapeutics
through which we can fulfill healthcare provider requests for
Leukine® (sargramostim) in countries outside the US and Canadian
markets. TannerGAP is pleased to be working with Partner
Therapeutics to expand the distribution of Leukine® (sargramostim)
to patients in need around the world.”
Robert Mulroy, CEO of Partner Therapeutics, added, “We are
pleased to be working with Tanner to support a named patient access
program to help meet the significant demand for Leukine® outside of
North America. Tanner has proven capabilities to support
physicians and help patients worldwide gain access to critical
medicines and we look forward to working in partnership to improve
access and treatments.”
About Tanner Pharma Group
For over 15 years, Tanner Pharma Group has provided highly
specialized pharmaceutical services to its partners. Companies
partner with Tanner Pharma to license and commercialize their
products in challenging international markets, develop and manage
their Global Access Programs, and source comparator drugs for
clinical trials and bioanalysis. For more information, visit
www.tannerpharma.com.
About Partner Therapeutics (PTx):
PTx is an integrated commercial stage biotech company focused on
the development and commercialization of therapeutics that improve
health and economic outcomes in the treatment of cancer. PTx's
development focus spans the entire range of cancer therapy from
primary treatments to supportive care. The company believes in
delivering great products in support of medical teams with the
purpose of creating the best possible outcomes for patients and
their families. For more information, visit www.PartnerTx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180524005266/en/
Tanner Pharma GroupLindsey Stevens,
704-552-8408lstevens@tannerpharma.com